Debating the Risks of Animal-to-Human Organ Transplants
Debate continues swirling around the issues of animal-to-human organ transplant, stirring up ethical concerns as well as scientific ones. This much is certain: the companies involved in the area saw potential problems coming a long time ago, but placed bets they hoped would establish them as leaders in a new and lucrative market. Those bets may yet pay off, but the players will now be watched far more closely than they were just a few years ago.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.